Glucosio B. Braun

Glucosio B. Braun is an injectable solution that contains glucose monohydrate as its sole active ingredient. It is supplied as a sterile aqueous solution for intravenous administration, typically used in parenteral nutrition and fluid therapy. The product conforms to European Union pharmaceutical standards and is classified as a carbohydrate solution (ATC code B05BB). Administration is performed by trained healthcare professionals in hospital or clinic settings.

Glucosio B. Braun is indicated for several clinical situations where rapid provision of glucose and fluid volume is required.

- Treatment of hypoglycemia when oral glucose is not feasible. - Component of parenteral nutrition regimens to supply carbohydrate calories. - Fluid and electrolyte replacement in patients unable to tolerate oral intake. - Expansion of extracellular fluid volume during resuscitation or surgery. - Dilution of other intravenous medications as a compatible carrier.

Adverse reactions to Glucosio B. Braun are generally related to its osmotic and caloric properties.

Common: - Transient hyperglycemia, especially in patients with impaired glucose tolerance. - Local irritation or pain at the infusion site. - Mild electrolyte shifts such as decreased serum potassium. - Nausea or vomiting if administered rapidly.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Fluid overload with pulmonary edema in susceptible individuals. - Allergic reactions ranging from urticaria to anaphylaxis. - Hyperosmolar hyperglycemic state in diabetic patients.

Safe use of Glucosio B. Braun requires assessment of patient condition and monitoring during therapy.

- Verify blood glucose levels before and during infusion to avoid hyperglycemia. - Assess fluid status; avoid in patients with congestive heart failure or renal impairment. - Use caution in neonates and pediatric patients due to limited metabolic capacity. - Monitor electrolytes, particularly potassium and sodium, during prolonged administration. - Do not exceed recommended infusion rates to prevent osmotic complications. - Store the solution according to manufacturer instructions and discard if visual inspection reveals particulates.

Glucosio B. Braun may interact with other intravenous agents, influencing glucose balance or fluid status.

Avoid: - Concurrent high‑dose insulin infusions without appropriate glucose monitoring. - Co‑administration with other hypertonic solutions that could exacerbate fluid overload.

Use with caution: - Diuretics, which may alter electrolyte balance during glucose infusion. - Beta‑blockers, which can mask signs of hypoglycemia. - Corticosteroids, which increase glucose production and may raise serum glucose levels.